BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32079691)

  • 1. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.
    Lin RJ; Lobaugh SM; Pennisi M; Chan HT; Batlevi Y; Ruiz JD; Elko TA; Maloy MA; Batlevi CL; Dahi PB; Giralt SA; Hamlin PA; Mead E; Noy A; Palomba ML; Santomasso BD; Sauter CS; Scordo M; Shah GL; Korc-Grodzicki B; Kim SJ; Silverberg ML; Brooklyn CA; Devlin SM; Perales MA
    Haematologica; 2021 Jan; 106(1):255-258. PubMed ID: 32079691
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.
    Hill BT; Roberts ZJ; Xue A; Rossi JM; Smith MR
    Bone Marrow Transplant; 2020 Jun; 55(6):1184-1187. PubMed ID: 31471571
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma.
    Xu H; Lv Q; Huang L; Cao W; Wang J; Meng F; Li C; Zheng M; Chen L; Mu K; Cheng J; Zhu L; Zhou J; Zhang Y; Wang N; Cao Y
    Cytotherapy; 2023 Feb; 25(2):185-191. PubMed ID: 36283943
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.
    Crombie JL; Jacobson CA; Redd R; Shouse G; Herrera AF; Chow VA; Gauthier J; Mullane E; Cahill K; Kline J; Romancik J; Cohen JB; Saucier A; Houot R; Armand P; Hess B
    Haematologica; 2023 Dec; 108(12):3433-3437. PubMed ID: 37259597
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute myeloid leukemia development soon after anti-CD19 chimeric antigen receptor T-cell infusion in a patient with refractory diffuse large B-cell lymphoma and pre-existing clonal hematopoiesis.
    Falini L; Venanzi A; Tini V; Innocente A; Ballanti S; Saldi S; Sivolella S; Pierini A; Aristei C; Tiacci E; Perriello VM; Falini B
    Haematologica; 2023 Jan; 108(1):290-294. PubMed ID: 35899391
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.
    Trujillo JA; Godfrey J; Hu Y; Huang J; Smith SM; Frigault MJ; DeFilipp Z; Appelbaum D; Pu Y; Feinberg N; Althaus T; Bishop MR; Riedell PA; Kline J
    Blood; 2021 Jun; 137(24):3454-3459. PubMed ID: 33881502
    [No Abstract]   [Full Text] [Related]  

  • 7. Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
    Allred J; Bharucha K; Özütemiz C; He F; Janakiram M; Maakaron J; Carrier C; Grzywacz B; Bachanova V
    Bone Marrow Transplant; 2021 Mar; 56(3):679-682. PubMed ID: 32764581
    [No Abstract]   [Full Text] [Related]  

  • 8. Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions.
    Salaroli A; Spilleboudt C; Bron D; Lewalle P
    Curr Opin Oncol; 2020 Sep; 32(5):434-441. PubMed ID: 32796231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.
    Chohan KL; Bansal R; Hathcock MA; Paludo J; Bennani NN; Johnston PB; Khurana A; Durani U; Wang Y; Ruff MW; Villasboas Bisneto JC; Ansell SM; Lin Y; Kenderian SS
    Leuk Lymphoma; 2024 Mar; 65(3):389-393. PubMed ID: 38031734
    [No Abstract]   [Full Text] [Related]  

  • 10. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy.
    Ababneh HS; Frigault MJ; Patel CG
    Hematol Oncol; 2024 Jan; 42(1):e3221. PubMed ID: 37679941
    [No Abstract]   [Full Text] [Related]  

  • 13. CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.
    Mohty M; Dulery R; Gauthier J; Malard F; Brissot E; Aljurf M; Bazarbachi A; Chabanon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian SS; Perales MA; Yakoub-Agha I; Nagler A
    Bone Marrow Transplant; 2020 Aug; 55(8):1525-1532. PubMed ID: 32305998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.
    Shargian L; Raanani P; Yeshurun M; Gafter-Gvili A; Gurion R
    Br J Haematol; 2023 Jan; 200(1):e4-e5. PubMed ID: 36281746
    [No Abstract]   [Full Text] [Related]  

  • 15. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
    Carpio C; Iacoboni G; Villacampa G; Catalá E; Bobillo S; Pérez A; Jiménez M; Segura L; Olivé M; Farriols A; Abrisqueta P; Valcárcel D; Carreras MJ; Bosch F; Barba P
    Leuk Lymphoma; 2021 Sep; 62(9):2288-2291. PubMed ID: 33899648
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-cell atlas of CD19 chimeric antigen receptor T cells.
    Li X; Henderson J; Gordon MJ; Sheikh I; Nastoupil LJ; Westin J; Flowers C; Ahmed S; Wang L; Neelapu SS; Strati P; Deng Q; Green MR
    Cancer Cell; 2023 Nov; 41(11):1835-1837. PubMed ID: 37738975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].
    Zhang Q; Xiao Y
    Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):788-792. PubMed ID: 36709176
    [No Abstract]   [Full Text] [Related]  

  • 19. [Research progress of CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Yang JJ; Sang W; Xu KL
    Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):849-852. PubMed ID: 31665867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.
    Havard R; Stephens DM
    Curr Hematol Malig Rep; 2018 Dec; 13(6):534-542. PubMed ID: 30362020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.